Lexaria Bioscience (LEXX) Q3 2024 Annual Earnings
LEXX·Reported November 26, 2024·Before market open
Lexaria Bioscience reported Q3 2024 revenue of $84.0K, missed analyst consensus of $100.0K by $16.0K. Diluted EPS came in at $-0.15, missed the $-0.11 consensus by $0.04.
Revenue
$84.0Kmissed by $16.0K
Consensus: $100.0KDiluted EPS
$-0.15missed by $0.04
Consensus: $-0.11
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Lexaria Bioscience's Q3 2024 earnings report.
Lexaria Bioscience (LEXX) reported Q3 2024 earnings on November 26, 2024 before market open.
Lexaria Bioscience reported revenue of $84.0K and diluted EPS of $-0.15 for Q3 2024.
Revenue missed the consensus estimate of $100.0K by $16.0K. EPS missed the consensus estimate of $-0.11 by $0.04.
You can read the 10-K periodic report (0001640334-24-001787) directly on SEC EDGAR. The filing index links above go to sec.gov.